@article {Yu2022.02.06.22270533, author = {Jingyou Yu and Ai-ris Y. Collier and Marjorie Rowe and Fatima Mardas and John D. Ventura and Huahua Wan and Jessica Miller and Olivia Powers and Benjamin Chung and Mazuba Siamatu and Nicole P. Hachmann and Nehalee Surve and Felix Nampanya and Abishek Chandrashekar and Dan H. Barouch}, title = {Comparable Neutralization of the SARS-CoV-2 Omicron BA.1 and BA.2 Variants}, elocation-id = {2022.02.06.22270533}, year = {2022}, doi = {10.1101/2022.02.06.22270533}, publisher = {Cold Spring Harbor Laboratory Press}, abstract = {The SARS-CoV-2 Omicron variant (B.1.1.529) has three major lineages BA.1, BA.2, and BA.31. BA.1 rapidly became dominant and has demonstrated substantial escape from neutralizing antibodies (NAbs) induced by vaccination2-4. BA.2 has recently increased in frequency in multiple regions of the world, suggesting that BA.2 has a selective advantage over BA.1. BA.1 and BA.2 share multiple common mutations, but both also have unique mutations1 (Fig. 1A). The ability of BA.2 to evade NAbs induced by vaccination or infection has not yet been reported. We evaluated WA1/2020, Omicron BA.1, and BA.2 NAbs in 24 individuals who were vaccinated and boosted with the mRNA BNT162b2 vaccine5 and in 8 individuals who were infected with SARS-CoV-2 (Table S1).Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe authors acknowledge NIH grant CA260476, the Massachusetts Consortium for Pathogen Readiness, the Ragon Institute, and the Musk Foundation (D.H.B.), as well as the Reproductive Scientist Development Program from the Eunice Kennedy Shriver National Institute of Child Health \& Human Development and Burroughs Wellcome Fund HD000849 (A.Y.C.).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The BIDMC institutional review board approved this study (2020P000361).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present work are contained in the manuscript}, URL = {https://www.medrxiv.org/content/early/2022/02/07/2022.02.06.22270533}, eprint = {https://www.medrxiv.org/content/early/2022/02/07/2022.02.06.22270533.full.pdf}, journal = {medRxiv} }